Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
—
—
—
EVOQ Remedies Limited is engaged in the pharmaceutical business. The Company is engaged in marketing, trading, and distribution of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic and anti-cold drugs, analgesic/ antipyretic and anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium, multivitamins, antioxidants, and injections. The Company also deals in the trading of active pharmaceutical ingredients (APIs). The Company's products include Abacavir Sulphate, Acetazolamide, Acyclovir, Adefovir Dipivoxil Allylestrenole, Alpha Beta Arteether, Alpha Lipoic Acid, Alprazolam, Amisulpride, Amoxycillin Trihydrate, Ampicillin Trihydrate, Artemether, Atracurium Besylate, Azathioprine, Azithromycin, Balofloxacin, Bendamustine, Biotin, Bosentan, Brimonidine, Bezafibrate Mupirocin, Mycophenolate, Mycophenolate, Nadifloxacin, Naltrexone HCL and more.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 9.32%